Table 4 Subjective self-assessment
From: Lidocaine for systemic sclerosis: a double-blind randomized clinical trial
Placebo group, n % | Lidocaine group, n % | P-value | |
|---|---|---|---|
Improvement of oral cavity opening | 6 (50%) | 7 (58.3%) | 0.682* |
Improvement of skin pigmentation | 8 (66.7%) | 7 (58.3%) | 0.673* |
Improvement of skin thickening | 12 (100%) | 12 (100%) | 1.00 |
Improvement of gastroesophageal complaints | 5 (41.7%) | 8 (66.7%) | 0.219* |
Improvement of joint pain | 5 (41.7%) | 7 (58.3%) | 0.414* |
The biggest drawback to trial participation | |||
None | 4 (33.3%) | 4 (33.3%) | 1.00 |
Oesophageal manometry | 8 (66.7%) | 8 (66.7%) | |
Would like to continue receiving treatment | 12 (100%) | 12 (100%) | 1.00 |